Antibody for resisting PHACTR1 protein and application thereof
By developing antibodies with specific VHCDR and VLCDR amino acid sequences, the problem of lack of specific drugs against PHACTR1 protein is solved, providing effective tools for detecting and treating atherosclerosis, significantly improving the specificity and effectiveness of disease treatment.
Patent Information
- Application Number
- CN202411468191.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-21
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-10-21
AI Technical Summary
Currently, there is a lack of specific drugs for PHACTR1 protein, and it is not effective in treating cardiovascular diseases such as atherosclerosis.
An antibody, which contains specific VHCDR and VLCDR amino acid sequences, is developed, capable of specifically binding to the PHACTR1 protein, for the detection and treatment of related diseases, including atherosclerosis.
It provides strong specific anti-PHACTR1 protein antibodies for disease detection and treatment, with wide practical application value, and can effectively recognize and bind PHACTR1 protein, which is significantly better than existing commercial antibodies.
Smart Images

Figure CN119039434A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antibody engineering pharmaceuticals, in particular to an antibody against PHACTR1 protein and an application thereof. Background Art
[0002] PHACTR1, the full name of which is phosphatase and actin regulator 1, belongs to the PHACTR family. It was first discovered by Patrick B. Allen's research group in the screening of protein phosphatase 1 (PP1) interacting proteins in brain tissue. Its mRNA is highly expressed in rat brain tissue, heart and lung tissue. This gene is highly conserved in evolution, with a homology of more than 95% between humans and mice, and more than 90% between humans and chickens. The main functional regions of PHACTR1 include 4 RPEL motifs (1 at the N-terminus and the other 3 at the C-terminus) and 1 nuclear localization sequence (NLS). The RPEL motif mainly mediates the binding of the protein to G-actin (globular actin), and the NLS sequence suggests that it has the possibility of entering the cell nucleus.
[0003] In recent years, many large-scale genome-wide association studies (GWAS) at home and abroad have suggested that multiple SNP sites on PHACTR1 are closely related to cardiovascular diseases such as atherosclerosis, hypertension, stroke, and diabetes. The existing technology has clearly shown that endothelial cell PHACTR1 promotes atherosclerosis. Animal experiments have found that PHACTR1 gene knockout can significantly inhibit the formation of atherosclerotic plaques in Apoe knockout mice. It is worth noting that the adventitia, media, and intima tissues of the aorta were separated and tested separately. PHACTR1 was only expressed in the intima tissue composed of vascular endothelial cells; and there was no expression in mouse bone marrow and macrophages. Using siRNA to knock down PHACTR1 in human umbilical vein endothelial cells (HUVEC), endothelial cell inflammation under resting conditions and under TNF-α stimulation was significantly inhibited, and the expression of adhesion molecules such as ICAM-1 and VCAM-1 and the adhesion of THP-1 cells to HUVEC were reduced. HUVEC cells were subjected to turbulent flow treatment (simulating pro-inflammatory and pro-atherosclerotic hemodynamics), and immunofluorescence results showed that overexpressed PHACTR1 was localized in the nucleus of HUVEC cells, suggesting that it may be involved in transcriptional regulation. In terms of molecular mechanism, RNAseq experiments using mRNA extracted from aortic endothelial cells of wild-type and PHACTR1 knockout mice showed that PHACTR1 knockout mainly affected genes related to inflammatory response and vascular development; transcription factor analysis results showed that genes regulated by transcription factor PPARγ in ECs were most significantly upregulated after PHACTR1 knockout. It is known that PPARγ plays an important protective role in endothelial function, and analysis of the PHACTR1 protein sequence found that both human and mouse PHACTR1 contain the LXXXIXXX (I / L) motif, a PPARγ transcriptional inhibition motif. Further in vivo and in vitro experiments showed that PHACTR1 inhibited the transcription factor activity of PPARγ, and the PPARγ inhibitor GW9662 could eliminate the protective effect of PHACTR1 knockout in endothelial cell inflammation and atherosclerosis. In summary, endothelial cell PHACTR1 is located in the nucleus and acts as a transcriptional co-inhibitory molecule to regulate the transcription of PPARγ target genes, causing endothelial cell inflammation and promoting the occurrence and development of cardiovascular diseases such as atherosclerosis. However, there are currently no specific drugs targeting PHACTR1. Summary of the invention
[0004] The purpose of the present invention is to provide an antibody against PHACTR1 protein and its application, so as to provide effective materials for further research on related diseases.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides an antibody comprising VHCDR1, VHCDR2 and VHCDR3;
[0007] and comprising VLCDR1, VLCDR2 and VLCDR3;
[0008] The amino acid sequence of VHCDR1 is shown in SEQ ID NO.3;
[0009] The amino acid sequence of VHCDR2 is shown in SEQ ID NO.4;
[0010] The amino acid sequence of VHCDR3 is shown in SEQ ID NO.5;
[0011] The amino acid sequence of the VLCDR1 is shown in SEQ ID NO.7;
[0012] The amino acid sequence of the VLCDR2 is GTN;
[0013] The amino acid sequence of VLCDR3 is shown in SEQ ID NO.9.
[0014] The present invention also provides an antibody, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO.2;
[0015] The amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO.6.
[0016] The present invention also provides an antigen binding fragment that binds to PHACTR1 antigen protein, comprising VHCDR1, VHCDR2 and VHCDR3;
[0017] and comprising VLCDR1, VLCDR2 and VLCDR3;
[0018] The amino acid sequence of VHCDR1 is shown in SEQ ID NO.3;
[0019] The amino acid sequence of VHCDR2 is shown in SEQ ID NO.4;
[0020] The amino acid sequence of VHCDR3 is shown in SEQ ID NO.5;
[0021] The amino acid sequence of the VLCDR1 is shown in SEQ ID NO.7;
[0022] The amino acid sequence of the VLCDR2 is GTN;
[0023] The amino acid sequence of VLCDR3 is shown in SEQ ID NO.9.
[0024] The present invention also provides a gene encoding the antibody, comprising a heavy chain variable region encoding gene as shown in SEQ ID NO.10 and a light chain variable region encoding gene as shown in SEQ ID NO.14.
[0025] The present invention also provides the use of the antibody, antigen binding fragment or encoding gene in preparing a reagent or a kit for detecting PHACTR1 protein.
[0026] The present invention also provides a reagent or a kit for detecting PHACTR1 protein, comprising the antibody or the antigen-binding fragment.
[0027] The present invention also provides the use of the antibody, antigen binding fragment or encoding gene in preparing a product that specifically binds to PHACTR1 protein in a sample to be tested.
[0028] The present invention also provides the use of the antibody, antigen binding fragment or encoding gene in preparing a product that specifically binds to PHACTR1 protein subtype A and / or protein subtype D in a sample to be tested.
[0029] The present invention also provides the use of the antibody, antigen binding fragment or encoding gene in the preparation of a drug for treating or assisting in treating a disease with the PHACTR1 protein as a molecular target.
[0030] The present invention also provides the use of the antibody, antigen binding fragment or encoding gene in preparing a drug for treating or assisting in treating atherosclerosis.
[0031] Beneficial effects of the present invention:
[0032] The anti-PHACTR1 protein antibody provided by the present invention has strong specificity, provides an effective material for immunodetection of PHACTR1 protein, can exert a therapeutic effect in related diseases, and has a wide range of practical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 This is the Western blot result of antibody recognition of antigen recombinant protein, where 1: protein molecular weight standard, 2: antigen recombinant protein;
[0034] Figure 2 This is the ELISA result of antibody recognizing antigen recombinant protein.
[0035] Figure 3The Western blot results of antibodies recognizing human and mouse PHACTR1 proteins, wherein the blue arrow indicates human PHACTR1 protein isoform A / mouse PHACTR1 protein isoform 4, and the red arrow indicates human PHACTR1 protein isoform D / mouse PHACTR1 protein isoform 5. 1: 293FT cell lysate overexpressing human PHACTR1 protein isoform A, 2: 293FT cell lysate overexpressing human PHACTR1 protein isoform D, 3: wild-type mouse brain tissue, 4: PHACTR1 knockout mouse brain tissue, 5: wild-type mouse lung tissue, 6: PHACTR1 knockout mouse lung tissue. DETAILED DESCRIPTION
[0036] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0037] SEQ ID NO.1:
[0038] VAQHHHTVLPSQIQHQLQYGSHGQHLPSTTGSLPMHPSGCRMIDELNKTLAMTMQRLESSEQRVPCSTSYHSSGLHSGDGVTKAGPMGLPEIRQVPTVVIECDDNKENVPHESDYEDSSCLYTREEEEEEEDEDDDSSLYTSSLAMKVCRKDSLA IKLSNRPSKRELEEKNILPRQTDEERLELRQQIGTKLTRRLSQRPTAEELEQRNILKPRNEQEEQEEKREIKRRLTRKLSQRPTVEELRERKILIRFSDYVEVADAQDYDRRADKPWTRLTAADKAAIRKELNEFKSTEMEVHELSRHLTRFHRP
[0039] SEQ ID NO.2:
[0040] EVKLLESGGGLVQPGGSLKLSCAASGFDFSGYWMSWVRQAPGKGLEWIGEIIPDSSTINYSPSLKDKFIISRDNAKKTLYLQMSNVRSEDTALYYCARPSYYSSTFAYWGQGTLVTVSA
[0041] SEQ ID NO.3:
[0042] GFDFSGYW
[0043] SEQ ID NO.4:
[0044] IIPDSSTI
[0045] SEQ ID NO.5:
[0046] ARPSYYSSTFAY
[0047] SEQ ID NO.6:
[0048] QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCVLWYSNLWVFGGGTKLTVL
[0049] SEQ ID NO.7:
[0050] TGAVTTSNY
[0051] SEQ ID NO.8:
[0052] GTN
[0053] SEQ ID NO.9:
[0054] VLWYSNLWV
[0055] SEQ ID NO.10:
[0056] GAGGTGAAGCTTCTCGAGTCTGGAGGTGGCCTGGTGCAGCCTGGAGGATCCCTGAAACTCTCCTGTGCAGCCTCAGGATTCGATTTTAGTGGATACTGGATGAGTTGGGTCCGGCAGGCTCCAGGAAAAGGGCTAGAATGGATTGGAGAGATTATTCCAGATAGCAGTACGATAAACTATTCGCCATCTCTAAAGGATAAATTCATCATCTCCAGAGACAACGCCAAAAAGACGCTGTACCTGCAAATGAGCAATGTGAGATCTGAGGACACAGCCCTTTATTACTGTGCAAGACCTAGTTACTACAGTTCTACCTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA
[0057] SEQ ID NO.11:
[0058] GGATTCGATTTTAGTGGATACTGG
[0059] SEQ ID NO.12:
[0060] ATTATTCCAGATAGCAGTACGATA
[0061] SEQ ID NO.13:
[0062] GCAAGACCTAGTTACTACAGTTCTACCTTTGCTTAC
[0063] SEQ ID NO.14:
[0064] CAGGCTGTTGTGACTCAGGAATCTGCACTCACCACATCACCTGGTGAAACAGTCACACTCACTTGTCGCTCAAGTACTGGGGCTGTTACAACTAGTAACTATGCCAACTGGGTCCAAGAAAAACCAGATCATTTATTCACTGGTCTAATAGGTGGTACCAACAACCGAGCTCCAGGTGTTCCTGCCAGATTCTCAGGCTCCCTGATTGGAGACAAGGCTGCCCTCACCATCACAGGGGCACAGACTGAGGATGAGGCAATATATTTCTGTGTTCTATGGTACAGCAACCTTTGGGTGTTCGGTGGAGGAACCAAACTGACTGTCCTA
[0065] SEQ ID NO.15:
[0066] ACTGGGGCTGTTACAACTAGTAACTAT
[0067] SEQ ID NO.16:
[0068] GGTACCAAC
[0069] SEQ ID NO.17:
[0070] GTTCTATGGTACAGCAACCTTTGGGTG
[0071] Example
[0072] I. Antigen Design
[0073] Due to the existence of different splice variants, PHACTR1 protein contains multiple subtypes, and human PHACTR1 has five protein subtypes, namely A, B, C, D, and E. The present invention selects a polypeptide in the common region of the five subtypes, namely the polypeptide at positions 271-580 in PHACTR1 protein subtype A, as an antigen to prepare anti-PHACTR1 monoclonal antibodies, and the amino acid sequence is shown in SEQ ID NO.1.
[0074] 2. Antigen Preparation
[0075] First, RNA from human umbilical vein endothelial cells was extracted and reverse transcribed into a cDNA library, and specific primers were designed and synthesized to amplify the PHACTR1 gene to obtain the full-length cDNA sequence of the human PHACTR1 gene; using this cDNA as a template, primers were designed to amplify the gene fragment corresponding to the 271-580 polypeptide (i.e., antigen) encoding human PHACTR1. The gene fragment was cloned into a Q vector (from Abmart), the cloned plasmid was amplified in Escherichia coli TOP10, and then expressed by Escherichia coli Rosetta; the prokaryotic recombinant protein of the 271-580 polypeptide of human PHACTR1 was obtained. After purification by Ni column affinity chromatography, the antigen was obtained.
[0076] 3. Animal Immunization
[0077] The purified antigen was used to immunize two healthy female BALB / c mice (8-12 weeks old). Routine immunization was performed four times with an interval of 2 weeks. For the first immunization, 30 μg of antigen was added with complete Freund's adjuvant and injected subcutaneously at multiple points; for the second to fourth immunizations, the antigen dose remained unchanged and incomplete Freund's adjuvant was added and injected subcutaneously at multiple points. Seven days after the third immunization, blood was taken from the mice to test the ELISA titer of the antiserum (recombinant protein antigen coated plate, 25 ng / well). Mice with an antiserum titer greater than 8K were immunized for the fourth time, and entered the fusion stage three days after immunization.
[0078] IV. Fusion and Subcloning
[0079] SP2 / 0 myeloma cells were revived and passaged in advance. On the day of fusion, spleens of immunized mice that met the requirements were taken and ground through a cell sieve, and the cells were resuspended in 1640 culture medium to obtain a spleen single cell suspension. BALB / c mice aged 6-10 weeks were taken, and after being killed and disinfected, frozen fructose solution was injected into the peritoneal cavity, and the abdomen was gently rubbed several times and then aspirated. The mouse peritoneal cells obtained were used as feeder cells. The spleen cells of immunized mice were mixed with SP2 / 0 myeloma cells in a ratio of 10:1 in 1640 culture medium, and 50% polyethylene glycol was slowly added for fusion. After the fusion was completed, the cells were diluted and spread on a 384-well plate, and cultured for 10-14 days using HAT selective culture medium. When the colony was larger than 3mm or covered 1 / 2 of the bottom of the well, the supernatant in each well was taken for ELISA detection of the response to the antigen, and affinity sorting was performed, and subclones with high affinity were selected. The selected subclone cells are plated in 96-well plates and cloned using the limiting dilution method. When clones are visible to the naked eye after 8-9 days of culture, the supernatant in each well is tested again by ELISA for the reaction to the antigen, and the cells with high affinity enter the next round of subcloning. Repeat the above steps until the positive rate of the cell line in the well is 100% (recognizing the corresponding antigen). At this time, it is considered that monoclonal antibodies have been obtained and the cell line has been successfully established.
[0080] 5. Preparation of Monoclonal Antibodies
[0081] The successfully established hybridoma cell line was cultured and subcultured in 1640 medium for large-scale amplification. The monoclonal antibody was mass-produced by inducing ascites in animals. Balb / c mice were intraperitoneally injected with Freund's incomplete adjuvant one week in advance, and the hybridoma cell suspension was injected into the mouse peritoneum one week later. 10-14 days after inoculation, the ascites was collected and centrifuged to obtain the supernatant rich in anti-PHACTR1 monoclonal antibodies.
[0082] VI. Antibody Identification
[0083] 1. Western blot detection of the antibody's recognition of the PHACTR1 recombinant antigen: 2ng recombinant protein recognition is one of the important parameters for determining whether an antibody is a good antibody. Western blot detection is performed on the corresponding antigen: 2ng recombinant protein is used for loading, transfer to the membrane, and observe the transfer results after staining with Ponceau red. After successful determination, proceed to the next step. The NC membrane is placed in 5% skimmed milk powder, blocked at room temperature for 1 hour, and then shaken at 4°C overnight. The milk powder needs to be fresh, pre-dissolved, and centrifuged at 3500rpm for 5min to remove insoluble particles. Incubate with diluted primary antibody at room temperature for 2 hours, wash 4 times with TBST, incubate with secondary antibody at room temperature for 45min, wash three times with TBST, and wash the membrane. Add ECL reagent and react for 1 minute before detecting the signal. The results show that the antibody can successfully recognize the antigen, such as Figure 1 shown.
[0084] 2. ELISA test of the sensitivity of the antibody to the antigen: the protein antigen coating concentration was 1ug / ml, and it was blocked with 5% milk PBS-T. The antibody was diluted as follows: 1: 3.125K / 6.25K / 12.5K / 25K / 50K / 100K, the primary antibody was incubated at 37℃ for 1 hour; the secondary antibody was incubated at 37℃ for 45 minutes; the color developing solution was added at 37℃ for 15 minutes and then the reaction was terminated, and the absorbance at a wavelength of 450nm was detected by an enzyme marker. The results showed that the antibody could bind to the antigen very well, such as Figure 2 shown.
[0085] 3. Western blot detection of the antibody against human and mouse PHACTR1 protein: The obtained monoclonal antibody was identified using full-length human PHACTR1 protein and wild-type or PHACTR1 knockout mouse brain and lung tissues. Western blot results showed that the antibody could well recognize overexpressed human PHACTR1 protein and PHACTR1 protein in mouse brain and lung tissues, and the recognition specificity was significantly better than that of the commercial PHACTR1 antibody (Santa Cruz, Cat. No. sc-514800). Figure 3 shown.
[0086] VII. Identification of variable region sequences of the antibody
[0087] The variable region of the monoclonal hybridoma was sequenced using the second-generation sequencing method. The hybridoma cell line was taken, the cells were lysed with Trizol lysis buffer, and the total RNA was extracted using HiPure RNA Mini Columns (Magen). The mRNA was reverse transcribed into a cDNA library using SMART Scribe reverse transcriptase (Takara) combined with oligonucleotide (oligo-dT) primers and template switching oligonucleotide (TSO) primers, and then the upstream primers anchored on TSO and the downstream primers located in the constant region of the heavy chain or light chain were used to obtain the heavy chain or light chain gene fragments in the first round of PCR amplification. After the PCR product was purified with magnetic beads, the second round of PCR amplification was performed using the Illumina TruSeq DNA library construction kit and the label primers to form a TruSeq dual-label library. The second-generation sequencing was performed using Illumina MiSeq PE300. The sequencing results were processed and analyzed using cutadapt (v1.9.1) and Pandaseq (v2.10) software packages to obtain gene sequences, and NCBI-IgBLAST (v1.17.0) was used to analyze the variable region sequences, especially the CDR region sequences of the heavy chain and light chain. The amino acid sequence of the antibody heavy chain variable region is shown in the sequence SEQ ID NO.2; the amino acid sequences of the three complementary determining regions CDR1, CDR2, and CDR3 on the heavy chain are shown in the sequences SEQ ID NO.3, SEQ ID NO.4, and SEQ ID NO.5, respectively. The amino acid sequence of the light chain variable region is shown in the sequence SEQ ID NO.6; the amino acid sequences of the three complementary determining regions CDR1, CDR2, and CDR3 on the heavy chain are shown in the sequences SEQ ID NO.7, SEQ ID NO.8, and SEQ ID NO.9, respectively. The nucleotide sequence of the heavy chain variable region is shown in SEQ ID NO.10; the nucleotide sequences of the three complementary determining regions CDR1, CDR2, and CDR3 on the heavy chain are shown in SEQ ID NO.11, SEQ ID NO.12, and SEQ ID NO.13, respectively. The nucleotide sequence of the light chain variable region is shown in SEQ ID NO.14; the nucleotide sequences of the three complementary determining regions CDR1, CDR2, and CDR3 on the light chain are shown in SEQ ID NO.15, SEQ ID NO.16, and SEQ ID NO.17, respectively.
[0088] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. An antibody, characterized in that Contains VHCDR1, VHCDR2 and VHCDR3; and comprising VLCDR1, VLCDR2 and VLCDR3; The amino acid sequence of VHCDR1 is shown in SEQ ID NO.3; The amino acid sequence of VHCDR2 is shown in SEQ ID NO.4; The amino acid sequence of VHCDR3 is shown in SEQ ID NO.5; The amino acid sequence of the VLCDR1 is shown in SEQ ID NO.7; The amino acid sequence of the VLCDR2 is GTN; The amino acid sequence of VLCDR3 is shown in SEQ ID NO.
9.
2. An antibody, characterized in that The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO.2; The amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO.
6.
3. An antigen-binding fragment that binds to PHACTR1 antigen protein, characterized in that: Contains VHCDR1, VHCDR2 and VHCDR3; and comprising VLCDR1, VLCDR2 and VLCDR3; The amino acid sequence of VHCDR1 is shown in SEQ ID NO.3; The amino acid sequence of VHCDR2 is shown in SEQ ID NO.4; The amino acid sequence of VHCDR3 is shown in SEQ ID NO.5; The amino acid sequence of the VLCDR1 is shown in SEQ ID NO.7; The amino acid sequence of the VLCDR2 is GTN; The amino acid sequence of VLCDR3 is shown in SEQ ID NO.
9.
4. The gene encoding the antibody according to claim 2, characterized in that: It comprises a heavy chain variable region encoding gene as shown in SEQ ID NO.10 and a light chain variable region encoding gene as shown in SEQ ID NO.
14.
5. Use of the antibody according to claim 1 or 2, the antigen-binding fragment according to claim 3 or the encoding gene according to claim 4 in the preparation of a reagent or a kit for detecting PHACTR1 protein.
6. A reagent or kit for detecting PHACTR1 protein, characterized in that: Contains the antibody according to claim 1 or 2 or the antigen-binding fragment according to claim 3.
7. Use of the antibody according to claim 1 or 2, the antigen-binding fragment according to claim 3 or the encoding gene according to claim 4 in preparing a product that specifically binds to PHACTR1 protein in a sample to be tested.
8. Use of the antibody according to claim 1 or 2, the antigen-binding fragment according to claim 3 or the encoding gene according to claim 4 in preparing a product that specifically binds to PHACTR1 protein subtype A and / or protein subtype D in a sample to be tested.
9. Use of the antibody according to claim 1 or 2, the antigen-binding fragment according to claim 3 or the encoding gene according to claim 4 in the preparation of a drug for treating or assisting in treating a disease with PHACTR1 protein as a molecular target.
10. Use of the antibody according to claim 1 or 2, the antigen-binding fragment according to claim 3 or the encoding gene according to claim 4 in the preparation of a drug for treating or assisting in the treatment of atherosclerosis.
Citation Information
Patent Citations
Application of autoantibodies in diagnosis and / or treatment of tumors
CN110687283A
AGENT FOR SUPPRESSING OR ENHANCING OF EXPRESSION OF EACH mRNA, AND AGENT FOR PREVENTION AND / OR TREATMENT OF IMMUNE SYSTEM DISEASE
JP2013112674A
Biomarkers for differentiating melanoma from benign nevus in the skin
US20120071343A1
